Institute of Inherited Metabolic Disorders, Charles University in Prague, First Faculty of Medicine, Ke Karlovu 2, Prague 2, Czech Republic.
Hum Mutat. 2010 Apr;31(4):445-55. doi: 10.1002/humu.21212.
Adenylosuccinate lyase (ADSL) deficiency is neurometabolic disease characterized by accumulation of dephosphorylated enzyme substrates SAICA-riboside (SAICAr) and succinyladenosine (S-Ado) in body fluids of affected individuals. The phenotypic severity differs considerably among patients: neonatal fatal, severe childhood, and moderate phenotypic forms correlating with different values for the ratio between S-Ado and SAICAr concentrations in cerebrospinal fluid have been distinguished. To reveal the biochemical and structural basis for this phenotypic heterogeneity, we expressed and characterized 19 ADSL mutant proteins identified in 16 patients representing clinically distinct subgroups. Respecting compound heterozygosity and considering the homotetrameric structure of ADSL, we used intersubunit complementation and prepared and characterized genotype-specific heteromeric mutant ADSL complexes. We correlated clinical phenotypes with biochemical properties of the mutant proteins and predicted structural impacts of the mutations. We found that phenotypic severity in ADSL deficiency is correlated with residual enzymatic activity and structural stability of the corresponding mutant ADSL complexes and does not seem to result from genotype-specific disproportional catalytic activities toward one of the enzyme substrates. This suggests that the S-Ado/SAICAr ratio is probably not predictive of phenotype severity; rather, it may be secondary to the degree of the patient's development (i.e., to the age of the patient at the time of sample collection).
腺嘌呤琥珀酸裂解酶 (ADSL) 缺乏症是一种神经代谢疾病,其特征是受影响个体的体液中存在去磷酸化的酶底物 SAICA-核糖苷 (SAICAr) 和琥珀酰腺苷 (S-Ado)。患者之间的表型严重程度差异很大:新生儿致命型、严重儿童型和中度表型与脑脊液中 S-Ado 和 SAICAr 浓度比值的不同值相关。为了揭示这种表型异质性的生化和结构基础,我们表达和表征了在 16 名患者中发现的 19 种 ADSL 突变蛋白,这些患者代表了临床不同的亚组。尊重复合杂合性,并考虑到 ADSL 的四聚体结构,我们使用亚基间互补作用,并制备和表征了特定基因型的异源三聚体突变 ADSL 复合物。我们将临床表型与突变蛋白的生化特性相关联,并预测了突变的结构影响。我们发现,ADSL 缺乏症的表型严重程度与相应突变 ADSL 复合物的残余酶活性和结构稳定性相关,而似乎不是由于对一种酶底物的特定基因型不成比例的催化活性所致。这表明 S-Ado/SAICAr 比值可能不能预测表型严重程度;相反,它可能是患者发育程度的结果(即患者在采集样本时的年龄)。